WeVote
Log In

Bill

Bill

SB 883

Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

89th Legislature (2025) Introduced by Bob Hall and 3 co-sponsors

Texas bill would establish statutory patient access to prescription drugs prescribed off-label for COVID-19 treatment, expanding physician prescribing flexibility.

Referred to Public Health
#covid-19(sb9ym) #healthcareproviders(i0387) #health--general(i0385) #health--otherdiseases&medicalconditions(i0383) #medicalboard #texas(v0644) #medicine&prescriptiondrugs(s7338) #physicians(s1282) #righttotreatact(p17xy)
0
WeVote Research Nonpartisan
Bill Summary · SB 883

Legislative bill overview

SB 883 would establish patient access rights to prescription drugs for off-label use specifically for COVID-19 treatment in Texas. The bill appears designed to allow physicians to prescribe FDA-approved medications for uses not officially approved by the FDA when treating COVID-19 patients. This expands on existing off-label prescribing practices by potentially creating explicit statutory protections or pathways for this medical practice.

Why is this important

Off-label prescribing already occurs legally in medical practice, but explicit statutory authorization could remove barriers physicians face when treating COVID-19 patients with alternative medications. This directly affects patient access to treatment options and could influence how quickly new or repurposed drugs reach COVID-19 patients during outbreaks, while also raising questions about medical oversight and evidence standards.

Potential points of contention

  • Medical evidence standards: Balancing rapid patient access against ensuring treatments have sufficient scientific evidence of safety and efficacy for COVID-19 specifically
  • Regulatory preemption concerns: Whether state law should create pathways that circumvent or complement federal FDA authority over drug approvals and labeling
  • Liability and oversight: Determining what protections or liability shields physicians and pharmacists receive when prescribing off-label, and what oversight mechanisms exist

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.